Tempus AI presents initial multimodal foundation model results for oncology insight generation at ASCO 2026
By
Stock Titan Editorial Team
Crisp on the outside, thoughtful on the inside. A keeper.
Summary
Tempus AI announced initial results from its Multimodal Foundation Model efforts at the 2026 ASCO Annual Meeting. The company is building novel biological foundation models and agentic workflows using over 500 petabytes of molecularly grounded data from more than 45 million de-identified patient journeys. The model, built on 2.5 million patient records and 500,000 sequences, achieved a 0.802 C-index and HR 4.536 in EGFR lung cancer analysis, suggesting potential for faster clinical trial design and diagnostics in oncology.
Key quotes
· 3 pulledTempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the latest results from its mission to build Multimodal Foundation Models at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Tempus has been building novel biological foundation models and agentic workflows by leveraging its more than 500 petabytes of rich, molecularly grounded data—more than 45 million total de-identified patient journeys.
Model built on 2.5M patient records and 500K sequences hit 0.802 C-index and HR 4.536 in EGFR lung cancer, hinting at faster trial design and diagnostics.
You might also wanna read
Gemma-Based AI Model Identifies Potential Cancer Therapy Pathway Through Conditional Immune Amplification
Researchers used a new 27 billion parameter foundation model called C2S-Scale 27B, built on Google's Gemma family of open models, to discove
blog.google·7mo ago
AI Foundation Model Improves Ophthalmologist Diagnostic Accuracy in Randomized Controlled Trial
Researchers developed EyeFM, a multimodal vision-language eyecare foundation model trained on 14.5 million ocular images from global dataset
nature.com·9mo ago